Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 957

Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA

Dr Hatem Soliman speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from a study looking at the use of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer.

He explains that the TVEC, an oncolytic virus modified to limit it's replication to in cancer cells, was incorporated with a taxane and anthracycline.

Dr Soliman reports that the combination was safe and feasible with no unexpected toxicities and that 55% of patients saw a complete eradication of the tumour from the breast.


Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation